Malignant gliomas are the most common primary brain tumors in adults. In the past 10 years significant advances in the treatment of this entity have been made, mainly owing to a better understanding of molecular pathways and biological behavior of the oncogenetic process. This review treats the proven effective and promising approaches with chemotherapy. The standard care for glioblastoma is surgery and concomitant radio- and chemotherapy with temozolomide (TMZ), followed by adjuvant treatment with TMZ. It has been demonstrated to be the most effective treatment protocol. This standardized care allows the application and study of new types of treatment mainly in recurrences and nonresponding patients. Many different approaches have been investigated: the combination of cytotoxic and cytostatic agents as well as molecular targeted therapies have given some encouraging results. Further intensified regimens with TMZ and the local postsurgical application of slow-release polymers loaded with carmustine remain to be defined. The characterization of molecular markers thus becomes particularly important for the stratification of patients raising the possibility to individualize treatment.

Insights into pharmacotherapy of malignant glioma in adults / Salvati, Maurizio; Alessandro, D'Elia; Anna Isabella, Formichella; Frati, Alessandro. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - STAMPA. - 10:14(2009), pp. 2279-2290. [10.1517/14656560903146910]

Insights into pharmacotherapy of malignant glioma in adults

SALVATI, Maurizio;FRATI, ALESSANDRO
2009

Abstract

Malignant gliomas are the most common primary brain tumors in adults. In the past 10 years significant advances in the treatment of this entity have been made, mainly owing to a better understanding of molecular pathways and biological behavior of the oncogenetic process. This review treats the proven effective and promising approaches with chemotherapy. The standard care for glioblastoma is surgery and concomitant radio- and chemotherapy with temozolomide (TMZ), followed by adjuvant treatment with TMZ. It has been demonstrated to be the most effective treatment protocol. This standardized care allows the application and study of new types of treatment mainly in recurrences and nonresponding patients. Many different approaches have been investigated: the combination of cytotoxic and cytostatic agents as well as molecular targeted therapies have given some encouraging results. Further intensified regimens with TMZ and the local postsurgical application of slow-release polymers loaded with carmustine remain to be defined. The characterization of molecular markers thus becomes particularly important for the stratification of patients raising the possibility to individualize treatment.
2009
bevacizumab; chemotherapy; erlotinib; glioblastoma; glioma; grade 3 gliomas; prognostic factors; survival; temozolomide
01 Pubblicazione su rivista::01a Articolo in rivista
Insights into pharmacotherapy of malignant glioma in adults / Salvati, Maurizio; Alessandro, D'Elia; Anna Isabella, Formichella; Frati, Alessandro. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - STAMPA. - 10:14(2009), pp. 2279-2290. [10.1517/14656560903146910]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/144475
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact